296 related articles for article (PubMed ID: 16799049)
1. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
Werth R; Schädler G
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
[TBL] [Abstract][Full Text] [Related]
2. Visual fields in young children treated with vigabatrin.
Agrawal S; Mayer DL; Hansen RM; Fulton AB
Optom Vis Sci; 2009 Jun; 86(6):767-73. PubMed ID: 19417698
[TBL] [Abstract][Full Text] [Related]
3. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
[TBL] [Abstract][Full Text] [Related]
4. Binasal visual field defects are not specific to vigabatrin.
Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
[TBL] [Abstract][Full Text] [Related]
5. Vigabatrin-associated visual field defects in children.
Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
[TBL] [Abstract][Full Text] [Related]
6. Visual fields at school-age in children treated with vigabatrin in infancy.
Gaily E; Jonsson H; Lappi M
Epilepsia; 2009 Feb; 50(2):206-16. PubMed ID: 19215279
[TBL] [Abstract][Full Text] [Related]
7. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
Conway M; Cubbidge RP; Hosking SL
Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
[TBL] [Abstract][Full Text] [Related]
8. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
[TBL] [Abstract][Full Text] [Related]
9. Vigabatrin and epilepsy: lessons learned.
Wild JM; Ahn HS; Baulac M; Bursztyn J; Chiron C; Gandolfo E; Safran AB; Schiefer U; Perucca E
Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
[TBL] [Abstract][Full Text] [Related]
10. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Riise P; Fledelius HC; Rogvi-Hansen Bà
Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
[TBL] [Abstract][Full Text] [Related]
11. Visual field constriction is not limited to children treated with vigabatrin.
Wohlrab G; Boltshauser E; Schmitt B; Schriever S; Landau K
Neuropediatrics; 1999 Jun; 30(3):130-2. PubMed ID: 10480207
[TBL] [Abstract][Full Text] [Related]
12. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
[TBL] [Abstract][Full Text] [Related]
13. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
[TBL] [Abstract][Full Text] [Related]
14. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
Mrugacz M; Bakunowicz-Łazarczyk A
Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
[TBL] [Abstract][Full Text] [Related]
15. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
Sorri I; Herrgård E; Viinikainen K; Pääkkönen A; Heinonen S; Kälviäinen R
Epilepsy Res; 2005 Jun; 65(1-2):117-20. PubMed ID: 15941649
[TBL] [Abstract][Full Text] [Related]
16. Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy.
Tseng YL; Lan MY; Lai SL; Huang FC; Tsai JJ
Acta Neurol Taiwan; 2006 Dec; 15(4):244-50. PubMed ID: 17214087
[TBL] [Abstract][Full Text] [Related]
17. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Newman WD; Tocher K; Acheson JF
Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
[TBL] [Abstract][Full Text] [Related]
18. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Camposano SE; Major P; Halpern E; Thiele EA
Epilepsia; 2008 Jul; 49(7):1186-91. PubMed ID: 18479386
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
[TBL] [Abstract][Full Text] [Related]
20. [Vigabatrin and alterations of the visual field].
Argumosa A; Herranz JL; Arteaga R; Barrasa J; Calles L; Armijo J
Rev Neurol; 1999 Apr 16-30; 28(8):741-5. PubMed ID: 10363313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
